SCRI

2025 ASCO Media Highlights

Issue link: https://uberflip.scri.com/i/1536260

Contents of this Issue

Navigation

Page 0 of 7

0714/25SCR019-18/R10RGB Media Highlights From the 2025 ASCO® Annual Meeting 1 Media Outlet Article / Coverage Blood Cancers Today Second-line ASC Monotherapy Safely Elicits High Molecular Response Rates in Non-T315l-Mutant CML-CP The Healthbook Company Ltd. Healthbook CHICAGO 2025 Newsroom Oncology Learning Network Asciminib Demonstrates High Molecular Responses Among Patients With CML-CP Targeted Oncology ASC2ESCALATE Clinical Trial in CML: Asciminib Dose Escalation Strategy Targeted Oncology Interim Analysis Highlights Asciminib's Efficacy and Safety in Second- Line CML VuMedi ASCO® 2025 Insights: Efficacy & Safety of Asciminib in Patients With CP- CML After 1 TKI - Interim Analysis of the Ph2 ASC2ESCALATE Trial David Andorsky, MD SCRI at Rocky Mountain Cancer Centers I The US Oncology Network Media Outlet Article / Coverage Cancer Network Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025 Benjamin Garmezy, MD SCRI Media Outlet Article / Coverage ASCO Daily News Podcast: ASCO25 Preview: Key Research Accelerating Cancer Care ASCO Daily News ASCO25 First Look: Dr. Erika Hamilton on VERITAC-2 ASCO Daily News VERITAC-2: Vepdegestrant Delivers Significantly Longer PFS Than Fulvestrant in ESR1-Mutated, ER-Positive/HER2-Negative Advanced Breast Cancer ASCO Daily News Podcast: Day 2: Top Takeaways From ASCO25 ASCO Daily News Podcast: ASCO25 Recap: CHALLENGE, DESTINY-Breast09, and More Erika Hamilton, MD SCRI Continued ➔

Articles in this issue

Links on this page

view archives of SCRI - 2025 ASCO Media Highlights